Fig. 1

Therapeutic administration of hUC-EVs-ATO alleviated aGVHD in a mouse model. A Experimental protocol of BMT mice or aGVHD mice. PBS, ATO, hUC-EVs or hUC-EVs-ATO were intraperitoneally injected into aGVHD mice for 5 consecutive days from day 7 post-transfusion. Data were collected on day 14. B Clinical scores of aGVHD mice in each group every 2 days from day 7 after transplantation. C Survival of aGVHD mice in each group. D Typical images of H&E staining of the skin, liver, ileum and colon of aGVHD mice in each group (magnification × 200). Scale bar, 100 μm. E Histological scores of the skin, liver, ileum and colon of aGVHD mice in each group. Data are shown as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, * represents a comparison between the hUC-EVs-ATO and aGVHD groups. ^#P < 0.05; ^##P < 0.01; ^###P < 0.001, ^# represents a comparison between the hUC-EVs-ATO and hUC-EVs groups. n.s. = not significant. There were six mice in each group